- Home
- ANVS vs MIST Comparison
ANVS vs MIST Comparison
Compare ANVS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | MIST |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 176.3M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANVS | MIST |
|---|---|---|
| Price | $2.26 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | 431.8K | ★ 2.1M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.63 |
| 52 Week High | $5.50 | $3.06 |
Technical Indicators
Market Signals| Indicator | ANVS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 46.10 |
| Support Level | $2.20 | N/A |
| Resistance Level | $2.29 | $2.01 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 29.94 | 48.10 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).